Tuberculosis (TB) is an infectious disease that represents a serious global threat, with estimations suggesting that one third of the world’s population is infected. Treating TB today requires long treatment duration and medicines must be administered orally in large doses, which leads to non-compliant patients. CPZEN-45 is a novel anti-TB drug candidate in pre-clinical development, in which pulmonary ...